All In Biotech

Drug Trial Radar · NCT00910429

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

237

Actual

Start

Jul 1, 2009

Primary completion

Aug 19, 2019

Study completion Aug 19, 2019

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
May 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.

Conditions

  • Pulmonary Hypertension

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: From administration of first dose of study medication up to 2 days after end of treatment with study medication, up to 10 years
  2. Number of Participants With DeathTime frame: From baseline to end of safety follow-up visit, up to 10 years (1 month more than End of study visit)

Locations

73 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    La Jolla, California

  • Site not named

    Sacramento, California

  • Site not named

    Iowa City, Iowa

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Dallas, Texas

  • Site not named

    Corrientes, Argentina

  • Site not named

    Prahran, Victoria, Australia

  • Site not named

    Vienna, Austria

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Prague, Czechia

  • Site not named

    Aarhus N, Denmark

  • Site not named

    Brest, France

  • Site not named

    Le Kremlin-Bicêtre, France

  • Site not named

    Rouen, France

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Hamburg, Germany

  • Site not named

    Heidelberg, Baden-Wurttemberg, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Würzburg, Bavaria, Germany

  • Site not named

    Giessen, Hesse, Germany

  • Site not named

    Hanover, Lower Saxony, Germany

  • Site not named

    Cologne, North Rhine-Westphalia, Germany

  • Site not named

    Homburg, Saarland, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Leipzig, Saxony, Germany

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.